Biond's High-Stakes Play: Tapping a Pharma Veteran to Guide Novel Cancer Drugs

MISGAV, Israel – June 22, 2026 – In the high-stakes world of biotechnology, executive appointments are rarely just about personnel. They are strategic signals, chess moves that reveal a company's ambitions and its readiness to transition from promising science to profitable medicine. The announcement today that Biond Biologics, a private Israeli biopharma, has appointed Dr. Giovanni Selvaggi as its new Chief Medical Officer is precisely such a move. It’s a clear declaration that the company believes its innovative cancer therapies are ready for the big leagues and that it has just hired a proven closer to guide them through the final, treacherous innings of clinical development.

Biond Biologics, founded in 2016, operates at the bleeding edge of immuno-oncology (I-O), a field now dominated by blockbuster checkpoint inhibitors like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. For a smaller, private entity to compete, it cannot simply follow the herd. It must innovate on a fundamental level, identifying novel biological pathways that the giants have overlooked. This is Biond’s gamble, and with two "first-in-class" clinical assets in its pipeline, the appointment of a seasoned CMO is not a luxury—it's a necessity for survival and success.

The 'Selvaggi Play': A Proven Closer for a Clinical-Stage Contender

To understand the significance of this hire, one must look past the standard corporate announcement and examine Dr. Selvaggi's curriculum vitae as a strategic asset. With over 30 years in oncology, his career is a roadmap of successful drug development, spanning academic research, Big Pharma leadership, and nimble biotech execution. He is not just a physician-scientist; he is a specialist in navigating the labyrinthine process from early-stage research to regulatory approval.

His most recent triumph at Xcovery Holdings, where he led the clinical and regulatory strategy for ensartinib, is a case in point. The drug, a next-generation ALK inhibitor, secured FDA approval in late 2024 for a specific subset of lung cancer patients, a major victory for a smaller player in a competitive field. Before that, his tenure at Bristol Myers Squibb saw him contributing to the regulatory filing of nivolumab (Opdivo), one of the foundational drugs of the I-O era. His fingerprints are also on the development of Novartis’s ceritinib (Zykadia). This isn’t just a track record; it’s a pattern of successfully identifying and prosecuting paths to market for novel oncology agents.

"Giovanni brings a unique combination of deep oncology expertise, immuno-oncology leadership, and hands-on experience advancing innovative therapies from early clinical development through regulatory filings," stated Tehila Ben Moshe, Ph.D., Co-Founder and CEO of Biond Biologics. Her words underscore the strategic imperative. As Biond advances its two lead programs, BND-22 and BND-67, it faces a gauntlet of complex trial designs, regulatory interactions, and data interpretation. Dr. Selvaggi has run this gauntlet successfully multiple times. His appointment is an injection of institutional knowledge and credibility, designed to de-risk the company's clinical execution in the eyes of investors and potential pharmaceutical partners.

Beyond Checkpoints: The Science Driving Biond's Gamble

The value of Dr. Selvaggi's expertise is magnified by the novelty of Biond's pipeline. The company is betting on two distinct, "first-in-class" mechanisms that aim to overcome the limitations of current immunotherapies.

The first asset, BND-22, is a monoclonal antibody targeting ILT2, an inhibitory receptor found on both innate and adaptive immune cells. While the market is saturated with drugs targeting the PD-1/PD-L1 axis, the ILT2 pathway represents a new frontier. By blocking ILT2, BND-22 aims to release a different set of brakes on the immune system, potentially unlocking anti-tumor activity in patients who don't respond to existing treatments. With BND-22 already in Phase 2 studies for solid tumors, the need for sophisticated clinical strategy is immediate. Biond is not alone in exploring this space—Gilead Sciences' acquisition of Tizona Therapeutics for its own ILT2 program signals that this is a valuable target. Biond's claim to a "first-in-class" lead puts pressure on the company to execute flawlessly, a task now falling squarely on Dr. Selvaggi's shoulders.

Even more ambitious is BND-67, which recently entered its first-in-human study. This drug targets a novel immune evasion mechanism described as "CD28 shedding." CD28 is a critical co-stimulatory molecule that provides a vital "go" signal for T-cells. Biond's research suggests that tumors can induce the shedding of this receptor from T-cells, effectively disarming them. BND-67 is designed to prevent this shedding, restoring the T-cells' ability to mount a powerful and sustained attack. As Dr. Selvaggi himself noted, this represents "a completely new approach to restoring physiological CD28 signaling." The mechanism is so novel that it has few direct competitors, offering a potential blue-ocean opportunity but also carrying the higher risk inherent in pioneering a new class of therapy.

The Immuno-Oncology Talent Hunt

Dr. Selvaggi's move to Biond Biologics also highlights a crucial dynamic in the modern biopharmaceutical landscape: the intense competition for proven leadership. In an industry where billions of dollars and countless patient lives hang on the outcomes of clinical trials, scientific innovation alone is not enough. "An experienced CMO is the difference between a promising molecule and an approved drug," noted one industry analyst. "They know how to design trials that the FDA will accept, how to interpret ambiguous data, and when to pivot or push forward. That experience is priceless."

For a private company like Biond, which operates outside the financial safety net of a large pharmaceutical firm, a hire of this caliber serves multiple purposes. It validates the science for a skeptical investment community, reassures clinical trial investigators, and positions the company as a serious contender for future partnerships or acquisition. It is a capital investment in human expertise, arguably as critical as the capital raised to fund the trials themselves.

As Biond moves forward, the focus will inevitably shift from its novel science to the hard reality of clinical data. The company is entering what its CEO calls a "transformative stage," where its foundational hypotheses will be tested in patients. Bringing Dr. Giovanni Selvaggi on board is the company's most decisive move yet to ensure that when those results come in, they have a leader who knows exactly how to turn data into a drug. The success of this high-stakes play will now depend on the potent combination of Biond's innovative biology and the seasoned judgment of its new clinical chief.